netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Recent Updates - Updated items

All Formulary Amendments

  Records 1 to 18 of 18


Details
UPD sitematrix Changed from 0 to
20/11/2023 12:45:21
(DavidS )
UPD FurtherInformation Changed from
  • 200mg tablets
  • Approved for treatment of advanced hepatocellular carcinoma only for people with Child-Pugh grade A liver impairment in line with NICE and NHS Commissioning Policy.
20/11/2023 12:45:21
(DavidS )
UPD Sorafenib (Nexavar®) updated formatting
20/11/2023 12:45:21
(DavidS )
UPD sitematrix Changed from 0 to
11/07/2023 17:28:41
(dmcdermott )
UPD FurtherInformation Changed from
11/07/2023 17:28:41
(dmcdermott )
UPD Sorafenib (Nexavar®) =
11/07/2023 17:28:41
(dmcdermott )
LDL Link Added : MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection : https://www.gov.uk/drug-safety-update/systemically-administered-vegf-pathway-inhibitors-risk-of-aneurysm-and-arte
06/07/2023 11:02:44
(rpaylor )
UPD sitematrix Changed from 0 to
17/12/2021 11:46:37
(LoweryM )
UPD FurtherInformation Changed from
17/12/2021 11:46:37
(LoweryM )
UPD Sorafenib (Nexavar®) formatting
17/12/2021 11:46:37
(LoweryM )
UPD Sorafenib (Nexavar®) NICE TA535
24/01/2019 15:03:55
(DavidS )
LDL Link Added : NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine : https://www.nice.org.uk/guidance/ta535
24/01/2019 15:03:17
(DavidS )
UPD Published from Draft Mode
27/10/2017 15:08:53
(DavidS )
LDL Link Added : NICE TA474Sorafenib for treating advanced hepatocellular carcinoma : https://www.nice.org.uk/guidance/ta474
26/10/2017 14:40:09
(DavidS )
UPD Sorafenib (Nexavar®) NICE TA474
26/10/2017 14:39:38
(DavidS )
UPD Sorafenib b
23/01/2017 15:36:58
(WhitehallJ )
UPD Sorafenib (Nexavar®) b
23/01/2017 15:33:27
(WhitehallJ )
UPD Sorafenib (Nexavar®) build
28/11/2016 15:50:20
(DavidS )

 

 

netFormulary